8 results about "Alopecia areata" patented technology

This invention belongs to the field of traditional Chinese medicine technology and discloses the application of *Saposhnikovia divaricata* in the preparation of drugs for treating alopecia areata. The preparation method of *Saposhnikovia divaricata* extract is as follows: *Saposhnikovia divaricata* is dried in the shade, pulverized, and then soaked in ethanol for at least 24 hours. The supernatant is then collected. This invention's *Saposhnikovia divaricata* extract can significantly shorten the time for skin to darken and the time for new hair to grow, enabling skin and hair to enter the growth phase more quickly. It can significantly increase the length and weight of newly grown hair and increase the number of primary hair follicles in the skin, thus promoting hair growth in alopecia areata and providing ideas and theoretical basis for the research and development of new drugs.

The application provides an application of a hair follicle immune homeostasis regulation strategy in treating alopecia diseases. A group of pathological LAMP3 + CCR7 + IL4I1 + DC3 dendritic cell subpopulation. A DC3 dendritic cell subpopulation marker gene Il4i1 Drive conditionally knockout one of the CGRP receptor complexes Calcrl The constructed spontaneous alopecia areata animal model can well simulate the progressive and active hair loss of alopecia areata patients, form stable hair loss patches, and combine with pathological changes such as hair follicle immune cell infiltration, which indicates that the dendritic cell CGRP signal loss is an important inducement for mediating systemic alopecia areata. The application also discloses a pharmaceutical composition or kit for preparing a drug for relieving / treating hair loss, improving hair follicle homeostasis, or enhancing hair growth / black coloration (reducing white hair), which comprises: (a) a JAK kinase inhibitor, and (b) a neuropeptide CGRP or a receptor agonist thereof.

The disclosure relates to a pharmaceutical composition comprising cyclosporine dissolved in a semifluorinated alkane and optionally a co-solvent, for use in the topical treatment of alopecia areata.

Use of compounds of formula I and formula II, and specifically relates to use of compound A1-A52, B1-B5, or C1-C36 in the preparation of a drug for treating and / or preventing an inflammatory or immune disease are provided. Compounds of A1-A52, B1-B5, or C1-C36 are used in the preparation of a drug for treating and / or preventing diseases such as rheumatoid arthritis, atopic dermatitis, hidradenitis suppurativa, vitiligo, dermatomyositis, alopecia areata, urticaria, multiple myositis, an interstitial lung disease, systemic lupus erythematosus, systemic sclerosis, and psoriasis.

The present disclosure relates to a novel crystalline form of a tosylate of diazadicyclic compound of formula (I), preparation method therefor, a pharmaceutical composition containing the crystal form, and the use of the crystal form in the preparation of a drug for treating alopecia areata, psoriasis and ulcerative colitis.

The application belongs to the field of medicine, and discloses a composition containing finasteride and use thereof. The composition contains finasteride, graphene and one or more pharmaceutically acceptable excipients. The composition of the application can be used to prevent and / or treat alopecia, seborrheic alopecia, androgenic alopecia, alopecia areata, or promote hair growth, and the amount of active ingredient is greatly reduced compared with finasteride tablets, thereby reducing the side effects associated therewith, and the composition has fast onset, long duration of action and good efficacy.

The application discloses a kind of anti-alopecia areata is extracted from Isatis indigotica Fort and Platycladus orientalis composite nanoparticles, its preparation method and application.The composite nanoparticles are composed of active ingredients, lipid materials, surfactants and water phase, the active ingredients are the mixture of Isatis indigotica Fort extract and Platycladus orientalis extract, and the composite nanoparticles are nanostructured lipid carriers.The preparation method includes dissolving active ingredients, liquid lipids and part of surfactants in organic solvents as oil phase, dissolving the remaining surfactants in water as water phase, adding oil phase to water phase, high-speed shearing emulsification, high-pressure homogenization, removing organic solvents, and cooling and solidifying.The composite nanoparticles can be used to prepare anti-alopecia areata products, significantly improve the transdermal absorption rate and follicular targeting of active ingredients, promote hair growth, and have the characteristics of high efficiency, stability and suitability for industrial production.

This invention provides a novel use of Atractylodes macrocephala essential oil for the prevention and treatment of hair loss and alopecia areata. The characteristic components of the Atractylodes macrocephala essential oil include: atractylenolide I, atractylenolide II, atractylenolide III, atractylone, β-elemene, hesperidin, and isohesperidin. The invention also provides a method for preparing essential oil compositions, pharmaceutical formulations, and uses for the prevention and treatment of hair loss and alopecia areata. This method reduces bitterness and the first-pass effect in the liver, resulting in more stable blood drug concentrations and improved patient compliance. Compared to existing methods, it has advantages such as better efficacy and no toxic side effects. Developing health products and pharmaceuticals for the prevention and treatment of hair loss and alopecia areata based on this method has great potential.